Berman Robert 4
4 · Biohaven Pharmaceutical Holding Co Ltd. · Filed Dec 31, 2019
Insider Transaction Report
Form 4
Berman Robert
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Shares
2019-12-30$0.61/sh+125,000$76,250→ 125,341 total - Sale
Common Shares
2019-12-30$52.95/sh−67,450$3,571,349→ 57,891 total - Sale
Common Shares
2019-12-30$53.43/sh−53,762$2,872,450→ 4,129 total - Sale
Common Shares
2019-12-30$54.89/sh−3,488$191,462→ 641 total - Sale
Common Shares
2019-12-30$55.97/sh−300$16,791→ 341 total - Exercise/Conversion
Employee Stock Option (right to buy)
2019-12-30−125,000→ 100,000 totalExercise: $0.61Exp: 2024-11-25→ Common Shares (125,000 underlying)
Holdings
- 550,000(indirect: By Trust)
Common Shares
- 240,500(indirect: By Trust)
Common Shares
- 50(indirect: By Spouse)
Common Shares
Footnotes (5)
- [F1]These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.23 - $53.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.23 - $53.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.64 - $55.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F5]The option, representing a right to purchase a total of 225,000 shares, was granted on November 26, 2014, and vested in four equal installments on November 26, 2014, 2015, 2016 and 2017